Literature DB >> 11916266

Growing significance of myeloperoxidase in non-infectious diseases.

Aline Hoy1, Brigitte Leininger-Muller, Dolphe Kutter, Gérard Siest, Sophie Visvikis.   

Abstract

Myeloperoxidase (MPO) is a glycoprotein released by activated polymorphonuclear neutrophils, which takes part in the defense of the organism through production of hypochlorous acid (HOCl), a potent oxidant. Since the discovery of MPO deficiency, initially regarded as rare and restricted to patients suffering from severe infections, MPO has attracted clinical attention. The development of new technologies allowing screening for this defect has permitted new advances in the comprehension of underlying mechanisms. Apart from its implications for host defense, the expression of MPO restricted to myeloid precursors makes MPO mRNA a good marker of acute myeloid leukemia. In addition, during the last few years, involvement of MPO has been described in numerous diseases such as atherosclerosis, lung cancer, Alzheimer's disease and multiple sclerosis. Both strong oxidative activity and MPO genetic polymorphism have been involved. This review summarizes the broad range of diseases involving MPO and points out the possible use of this protein as a new clinical marker and a future therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11916266     DOI: 10.1515/CCLM.2002.002

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  15 in total

1.  Myeloperoxidase deficiency attenuates systemic and dietary iron-induced adverse effects.

Authors:  Xia Xiao; Piu Saha; Beng San Yeoh; Jennifer A Hipp; Vishal Singh; Matam Vijay-Kumar
Journal:  J Nutr Biochem       Date:  2018-08-21       Impact factor: 6.048

2.  Low-intensity infrared laser increases plasma proteins and induces oxidative stress in vitro.

Authors:  Adenilson de Souza da Fonseca; Giuseppe Antonio Presta; Mauro Geller; Flavia de Paoli; Samuel Santos Valença
Journal:  Lasers Med Sci       Date:  2011-06-24       Impact factor: 3.161

3.  Neutrophil-Derived Myeloperoxidase Facilitates Both the Induction and Elicitation Phases of Contact Hypersensitivity.

Authors:  Anna Strzepa; Cody J Gurski; Landon J Dittel; Marian Szczepanik; Kirkwood A Pritchard; Bonnie N Dittel
Journal:  Front Immunol       Date:  2021-01-25       Impact factor: 7.561

4.  Kinetic investigation of myeloperoxidase upon interaction with copper, cadmium, and lead ions.

Authors:  Maryam Shabani; Mohsen Ani; Ahmad Movahedian; Seyed Ziyae Aldin Samsam Shariat
Journal:  Iran Biomed J       Date:  2011

5.  Activatable magnetic resonance imaging agents for myeloperoxidase sensing: mechanism of activation, stability, and toxicity.

Authors:  Elisenda Rodríguez; Mark Nilges; Ralph Weissleder; John W Chen
Journal:  J Am Chem Soc       Date:  2010-01-13       Impact factor: 15.419

6.  Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of Alzheimer disease.

Authors:  Richard A Maki; Vladimir A Tyurin; Robert C Lyon; Ronald L Hamilton; Steven T DeKosky; Valerian E Kagan; Wanda F Reynolds
Journal:  J Biol Chem       Date:  2008-12-05       Impact factor: 5.157

7.  Myeloperoxidase assay in plasma and peritoneal fluid of horses with gastrointestinal disease.

Authors:  Sigrid Grulke; Thierry Franck; Monika Gangl; Fabrice Péters; Alexandra Salciccia; Ginette Deby-Dupont; Didier Serteyn
Journal:  Can J Vet Res       Date:  2008-01       Impact factor: 1.310

8.  Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase.

Authors:  Michael O Breckwoldt; John W Chen; Lars Stangenberg; Elena Aikawa; Elisenda Rodriguez; Shumei Qiu; Michael A Moskowitz; Ralph Weissleder
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-14       Impact factor: 11.205

9.  Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel.

Authors:  Apurva R Patel; Mahavir B Chougule; Townley I; Ram Patlolla; Guangdi Wang; Mandip Singh
Journal:  Pharm Res       Date:  2013-01-30       Impact factor: 4.200

10.  N-acetyl lysyltyrosylcysteine amide inhibits myeloperoxidase, a novel tripeptide inhibitor.

Authors:  Hao Zhang; Xigang Jing; Yang Shi; Hao Xu; Jianhai Du; Tongju Guan; Dorothee Weihrauch; Deron W Jones; Weiling Wang; David Gourlay; Keith T Oldham; Cheryl A Hillery; Kirkwood A Pritchard
Journal:  J Lipid Res       Date:  2013-07-24       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.